Philippines - English - FDA (Food And Drug Administration)

logenex pharm gmbh; importer: unilab, inc.; distributor: unilab, inc. - bortezomib - lyophilized powder for solution for injection (i.v./s.c.) - 3.5 mg

United States - English - NLM (National Library of Medicine)

genexa inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - purpose pain reliever/fever reducer uses temporarily reduces fever and relieves minor aches and pains due to: - the common cold - headache - toothache - flu - sore throat

United States - English - NLM (National Library of Medicine)

genexa inc. - sennosides (unii: 3fyp5m0ijx) (sennosides - unii:3fyp5m0ijx) - purpose laxative uses - relieves occasional constipation (irregularity) - generally produces bowel movement in 6 to 12 hours

United States - English - NLM (National Library of Medicine)

genexa inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - purpose pain reliever/fever reducer uses - temporarily relieves minor aches and pains due to: the common cold headache backache minor pain of arthritis toothache muscular aches premenstrual and menstrual cramps - the common cold - headache - backache - minor pain of arthritis - toothache - muscular aches - premenstrual and menstrual cramps - temporarily reduces fever

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - genexol is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer; in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - genexol is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer (nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - paclitaxel, quantity: 6 mg/ml - injection, solution - excipient ingredients: ethanol absolute; peg-35 castor oil - genexol is indicated for: primary treatment of ovarian cancer in combination with a platinum agent; treatment of metastatic carcinoma of the ovary and of the breast after failure of standard therapy; adjuvant treatment of node positive breast cancer administered sequentially to doxorubicin and cyclophosphamide; treatment of metastatic cancer of the breast, in combination with trastuzumab (herceptin), in patients who have tumours that over-express her-2 and who have not received previous chemotherapy for their metatastic disease; treatment of non-small cell lung cancer(nsclc); in combination with gemcitabine (gemzar), is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/ neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated.